Is Repaglinida [INN-Spanish] Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use Repaglinida [INN-Spanish]? Is Repaglinida [INN-Spanish] safe for nursing mother and child? Does Repaglinida [INN-Spanish] extracts into breast milk? Does Repaglinida [INN-Spanish] has any long term or short term side effects on infants? Can Repaglinida [INN-Spanish] influence milk supply or can Repaglinida [INN-Spanish] decrease milk supply in lactating mothers?

• DrLact safety Score for Repaglinida [INN-Spanish] is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of Repaglinida [INN-Spanish] may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that Repaglinida [INN-Spanish] may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using Repaglinida [INN-Spanish] .
• It is recommended to evaluate the advantage of not breastfeeding while using Repaglinida [INN-Spanish] Vs not using Repaglinida [INN-Spanish] And continue breastfeeding.
• While using Repaglinida [INN-Spanish] Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Meglitinide drugs stimulate secretion of endogen insulin.There is a potential risk of hypoglucemia.Oral anti-diabetic drugs are useless for treatment of diabetes type 1. For diabetes type 2, diet and exercise are advisable. Breastfeeding helps to lower glucemia level. See section on Maternal diabetes mellitus

No information is available on the use of Repaglinida [INN-Spanish] during breastfeeding. Repaglinida [INN-Spanish] is a weak acid that is over 98% protein bound, so it is unlikely to pass into breastmilk in clinically important amounts. If Repaglinida [INN-Spanish] is required by the mother, it is not a reason to discontinue breastfeeding. Monitor breastfed infants for signs of hypoglycemia such as jitteriness, excessive sleepiness, poor feeding, seizures cyanosis, apnea, or hypothermia. If there is concern, monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with Repaglinida [INN-Spanish].[1] However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.